136 related articles for article (PubMed ID: 12407433)
1. A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation.
Bolwell BJ; Kalaycio M; Sobecks R; Andresen S; Kuczkowski E; Bernhard L; Lomax R; Kohuth J; Mendiola S; Rybicki L; Pohlman B
Bone Marrow Transplant; 2002 Nov; 30(9):587-91. PubMed ID: 12407433
[TBL] [Abstract][Full Text] [Related]
2. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
3. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
[TBL] [Abstract][Full Text] [Related]
4. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
5. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
6. A novel preparative regimen for autologous transplant in non-Hodgkin's lymphoma: long-term experience with etoposide and thiotepa.
McCoy AG; Smith EP; Atkinson ME; Baranski B; Kahl BS; Juckett M; Mitchell T; Gangnon R; Longo WL
Bone Marrow Transplant; 2004 Jan; 33(1):19-24. PubMed ID: 14704653
[TBL] [Abstract][Full Text] [Related]
7. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
8. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
[TBL] [Abstract][Full Text] [Related]
9. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies.
Fanning SR; Rybicki L; Kalaycio M; Andresen S; Kuczkowski E; Pohlman B; Sobecks R; Sweetenham J; Bolwell B
Br J Haematol; 2006 Nov; 135(3):374-81. PubMed ID: 16995885
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
Dorr RT; Briggs A; Kintzel P; Meyers R; Chow HH; List A
Bone Marrow Transplant; 2003 Apr; 31(8):643-9. PubMed ID: 12692603
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
Freytes CO; Ratanatharathorn V; Taylor C; Abboud C; Chesser N; Restrepo A; Arango J; Odenheimer D
Clin Cancer Res; 2004 Dec; 10(24):8318-24. PubMed ID: 15623608
[TBL] [Abstract][Full Text] [Related]
13. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
15. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
16. Multivariate analysis of factors influencing oral mucositis in allogeneic hematopoietic stem cell transplantation.
Ohbayashi Y; Imataki O; Ohnishi H; Iwasaki A; Ogawa T; Inagaki N; Shigeta H; Ohue Y; Tasaka T; Kitanaka A; Kubota Y; Tanaka T; Ishida T; Miyake M
Ann Hematol; 2008 Oct; 87(10):837-45. PubMed ID: 18553082
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of malignant lymphoma by autologous hematopoietic stem cell transplantation combined with high dose radiotherapy and chemotherapy].
Wang HQ; Cui XZ; Ren XB; Liu XM; Dai RZ; Zhang HL; Huang WY; Li W; Hao XS
Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(11):948-51. PubMed ID: 12899794
[TBL] [Abstract][Full Text] [Related]
18. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
19. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies.
Bolwell BJ; Pohlman B; Rybicki L; Sobecks R; Dean R; Curtis J; Andresen S; Koo A; Mineff V; Kalaycio M; Sweetenham JW
Bone Marrow Transplant; 2007 Sep; 40(5):437-41. PubMed ID: 17618321
[TBL] [Abstract][Full Text] [Related]
20. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
